India, Pakistan & Cambodia Tuberculosis Treatment Market is segmented By Therapy Type (First Line Therapy (Isoniazid (INH), Rifampicin (RIF), Ethambutol (EMB), Pyrazinamide (PZA), Streptomycin (SM), Others), Second Line Therapy (Capreomycin (Capastat), Streptomycin, Levofloxacin (Levaquin), Ethionamide (Trecator), Others), Combination Drugs), By Disease Type (Active TB, Latent TB), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and By Region – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The India, Pakistan & Cambodia Tuberculosis Treatment Market is expected to grow at a high CAGR during the forecasting period (2024-2031).
Tuberculosis (TB), known as poor man’s disease, is caused by Mycobacterium tuberculosis germs that are spread from person to person through the air.
TB usually affects the lungs and affects the other parts of the body such as the brain, the kidneys, or the spine.
In 2017, the number of deaths by tuberculosis in Cambodia amounted to 19 deaths per hundred thousand people.
By drug type, the tuberculosis drug market is segmented into first-line drugs therapy, second-line drugs therapy, and combination drugs therapy.
The first-line drug therapy segment holds the most significant share in 2018, owing to the usage of a combination of first-line drugs, around 90% of individuals with drug-susceptible TB can be cured. Any delay and discontinuity during this treatment can lead to treatment failure and the emergence of drug resistance.
The first-line anti-TB regimen comprises a daily dosage of isoniazid, rifampicin, pyrazinamide, and ethambutol for two months, followed by a daily dosage of isoniazid and rifampicin for four months
